A PBM audit finding built on usual and customary pricing can turn one miscalculated cash price into a six-figure recoupment demand. The usual and customary (U&C) price is the lowest amount a pharmacy would charge a cash-paying customer for a prescription on the day it was dispensed, and federal Medicaid rules cap reimbursement at that number, not at a shelf price. Pharmacies that run membership pricing, loyalty clubs, or in-store discount programs to compete for cash customers often report a U&C figure that does not match what those programs actually charged, and PBM audit teams build recoupment demands out of exactly that gap.
How the Usual and Customary Price Is Calculated
Under 42 CFR 447.512(b), a state Medicaid program may not pay a pharmacy more than the lower of the estimated acquisition cost plus a dispensing fee, or the pharmacy's usual and customary charge to the general public. That charge is the actual lowest amount the pharmacy would accept from a specific cash-paying customer for that exact drug on that exact day, discounts included, not an average, a list price, or a manufacturer's suggested price. Commercial PBM contracts import the same definition into the U&C field on every claim, insured or not. A pharmacy that quotes one price at the counter and reports a higher U&C figure to the PBM has created the discrepancy an audit is built to find.
Membership and Discount Program Pricing Traps
The trap is a standing pricing program that never gets reconciled against what the pharmacy reports as U&C, not a single bad claim. Flat-rate generic lists, senior discount days, and in-house membership clubs each create a real cash price, and most state Medicaid rules treat that price as the pharmacy's usual and customary charge, not as a promotional exception. Walgreens learned this directly: the Department of Justice's Southern District of New York announced a $60 million settlement in January 2019 after Walgreens sought Medicaid reimbursement without disclosing the lower prices it charged customers through its own Prescription Savings Club. Any pharmacy running a membership or discount program while reporting a higher number in the U&C field carries the same exposure.
Extrapolation and the Recoupment Theory
A pricing mismatch in a sample of claims becomes the PBM's basis for extrapolation, projecting the error rate across the full lookback period instead of repricing only the claims actually reviewed. A handful of flagged fills can become a recoupment demand covering years of dispensing. The theory holds that if the pharmacy underreported its cash price on the sampled claims, it did so on every similar claim in the window. Not every jurisdiction accepts that leap. Minnesota's pharmacy benefit manager audit statute, Minn. Stat. § 62W.09, requires findings to rest on actual overpayment and bars extrapolation unless state or federal law specifically requires it. Where extrapolation is permitted, contesting the sampling methodology through a timely audit appeal is often the difference between a five-figure and a six-figure demand.
Building the Response to a U&C Finding
A defensible response starts with the pharmacy's own point-of-sale records: register logs, discount program terms, and the price actually charged the day each sampled claim was filled. Those records either match the submitted U&C field or they do not, and that comparison should happen before the production deadline, not after. The response also tests the extrapolation math itself, since a flawed sample or an unrepresentative claim selection can undercut the entire projected demand. Pharmacies working through the broader document request should follow the same deadline and preservation discipline set out in How to Respond to a PBM Audit Letter, since a U&C finding is typically one line item inside a larger audit.
A usual and customary finding is the PBM's opening argument for extrapolating a pricing gap across every claim in the lookback period, not a dispute about the one flagged claim.
Why Early Legal Counsel Is Critical
It is critical that pharmacies promptly retain experienced healthcare defense counsel upon receiving a PBM audit notice, a recoupment demand, or any government inquiry tied to pricing. Early legal intervention can protect the pharmacy's rights, ensure the audit response accurately reflects actual point-of-sale pricing, avoid inadvertent admissions in the production, and preserve every available defense to the extrapolation methodology. Delaying representation can significantly affect the outcome and expose the pharmacy to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance defends pharmacies against PBM audit findings built on usual and customary pricing, including the extrapolated recoupment demands that follow a membership or discount program review. Our team includes a former federal prosecutor and a former senior executive from a major pharmacy benefit manager, a background that shapes how these findings are constructed and where they are vulnerable to challenge. If your pharmacy has received an audit letter citing a U&C pricing discrepancy, contact us for a free, confidential consultation.
